3-Mar-2026 6:00 AM CST - Business Wire Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) today reported financial and business results for the fourth quarter and full year ended December 31, 2025. 2025 was a year of meaningful advancement for Amylyxs pivotal avexitide program in post-bariatric hypoglycemia, as well as progress across our broader pipeline, said Joshua Cohen and Justin Klee, Co-CEOs of Amylyx. In 2026, our primary focus is on our Phase 3 LUCIDITY trial of av
6-Nov-2025 6:00 AM CST - Business Wire Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) today reported financial and business results for the third quarter ended September 30, 2025. Entering the final months of 2025, we are focused on execution as we head toward a transformative year in 2026, with topline data expected from the pivotal Phase 3 LUCIDITY trial, said Joshua Cohen and Justin Klee, Co-CEOs of Amylyx. We continue to advance our lead asset avexitide, an investiga
13-Jul-2025 4:00 PM CST - Business Wire Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025 Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (Amylyx or the Company) today announced the presentation of new exploratory analyses from the Phase 2 PREVENT and Phase 2b clinical trials of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist for the treatment of post-bariatric hypoglycemia (PBH) at the Endocrine Societys annual meeting (ENDO 2025). In the Phase 2b trial, avexitide 90 mg once daily, the dose being
3-Mar-2026 6:00 AM CST - Business Wire Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) today reported financial and business results for the fourth quarter and full year ended December 31, 2025. 2025 was a year of meaningful advancement for Amylyxs pivotal avexitide program in post-bariatric hypoglycemia, as well as progress across our broader pipeline, said Joshua Cohen and Justin Klee, Co-CEOs of Amylyx. In 2026, our primary focus is on our Phase 3 LUCIDITY trial of av
6-Nov-2025 6:00 AM CST - Business Wire Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) today reported financial and business results for the third quarter ended September 30, 2025. Entering the final months of 2025, we are focused on execution as we head toward a transformative year in 2026, with topline data expected from the pivotal Phase 3 LUCIDITY trial, said Joshua Cohen and Justin Klee, Co-CEOs of Amylyx. We continue to advance our lead asset avexitide, an investiga
13-Jul-2025 4:00 PM CST - Business Wire Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025 Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (Amylyx or the Company) today announced the presentation of new exploratory analyses from the Phase 2 PREVENT and Phase 2b clinical trials of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist for the treatment of post-bariatric hypoglycemia (PBH) at the Endocrine Societys annual meeting (ENDO 2025). In the Phase 2b trial, avexitide 90 mg once daily, the dose being
